Médecine

Paramédical

Autres domaines


S'abonner

The challenge of the new tuberculosis drugs - 28/03/17

Doi : 10.1016/j.lpm.2017.01.016 
Simon Tiberi 1, 9, Ruaridh Buchanan 1, 9, José A. Caminero 2, 3, Rosella Centis 4, Marcos Abdo Arbex 5, Miguel Salazar 6, Jessica Potter 7, 8, Giovanni Battista Migliori 4,
1 Barts Health NHS Trust, Royal London Hospital, Division of Infection, 80 Newark Street, E1 2ES London, United Kingdom 
2 University Hospital of Gran Canaria “Dr Negrin”, Pneumology Department, Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain 
3 International Union against Tuberculosis and Lung Disease, Paris, France 
4 Maugeri Care and Research Institute, IRCCS, World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, Italy 
5 University Center of Araraquara Hospital Nestor Goulart Reis, São Paulo State Secretary of Health, São Paulo, Brazil 
6 Tuberculosis Clinic, National Institute of Respiratory Diseases of Mexico (INER), Mexico City, Mexico 
7 Barts Health NHS Trust, Royal London Hospital, Department of Respiratory Medicine, 80, Newark Street, E1 2ES London, United Kingdom 
8 Blizard Institute, Barts and the London School of Medicine and Dentistry, Centre for Primary Care and Public Health, E1 2AB London, United Kingdom 

Giovanni Battista Migliori, Maugeri Care and Research Institute, IRCCS, World Health Organization Collaborating Centre for Tuberculosis and Lung Diseases, Tradate, Italy.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Summary

Tuberculosis (TB) continues to cause more deaths worldwide than any other single infectious disease. Even though tuberculosis appears to be decreasing in incidence globally for some time, the proportion of drug resistance is increasing, contributing to greater complexity, morbidity and mortality as well as cost. Since the advent of rifampicin in the 1960s, and the implementation of standard quadruple anti-tuberculosis regimen in the late 1970s, no new drugs have been changed the first line regimen. This regimen is effective however it is pill burden, and duration has not received investment and innovation. Drug-resistant regimens are long and frequently poorly tolerated due to significant toxicity. This review is an update on what is new in the treatment of drug-susceptible and drug-resistant tuberculosis, new TB drugs currently being used and studied in clinical trials are also mentioned. Fortunately, there have been many significant advances in this field in recent years. The horizon is changing with the new WHO shorter multidrug-resistant tuberculosis regimens and with the increasing availability of new or repurposed drugs like bedaquiline, delamanid, clofazimine and linezolid. These drugs pose new challenges relating to their rational use to prevent selection of resistant strains of Mycobacterium tuberculosis even before a new regimen has been studied. The availability of these new drugs is offering hope and new possibilities for saving patients who had few or no treatment options. Their use and combination into effective regimens need to be studied; trials are in progress. It is hoped that soon we will be able to treat sensitive and drug-resistant cases with a universal regimen, this would revolutionise treatment and take us another step closer towards elimination.

Le texte complet de cet article est disponible en PDF.

Plan


© 2017  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 46 - N° 2P2

P. e41-e51 - mars 2017 Retour au numéro
Article précédent Article précédent
  • The cursed duet today: Tuberculosis and HIV-coinfection
  • Simon Tiberi, Anna Cristina C. Carvalho, Giorgia Sulis, Devan Vaghela, Adrian Rendon, Fernanda C. de Q. Mello, Ananna Rahman, Nashaba Matin, Ali Zumla, Emanuele Pontali
| Article suivant Article suivant
  • Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis
  • Ruvandhi R. Nathavitharana, Patricia Bond, Angela Dramowski, Koot Kotze, Philip Lederer, Ingrid Oxley, Jurgens A. Peters, Chanel Rossouw, Helene-Mari van der Westhuizen, Bart Willems, Tiong Xun Ting, Arne von Delft, Dalene von Delft, Raquel Duarte, Edward Nardell, Alimuddin Zumla

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.